ThromboGenics NV


LEUVEN, Belgium, October 19, 2011 - If Approved, Ocriplasmin Will be the First Pharmacological Treatment for Symptomatic Vitreomacular Adhesion (VMA) Including Macular Hole ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) for ocriplasmin (2.5 mg/ml, solution for injection) for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole.

LEUVEN, Belgium, August 22, 2011 - New data presented by leading retinal specialists Dr Pravin U.Dugel,MD(Phoenix,AZ) and Dr Peter K.

LEUVEN, Belgium, August 9, 2011 - Retinal community showing increasing interest in ocriplasmin's clinical profile ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today issued an update on its filing plans and pre-commercialization activities for its lead product ocriplasmin.

LEUVEN, Belgium, June 7, 2011 - ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that Patrik De Haes, the Chief Executive Officer of ThromboGenics will present an overview of the Company's strategy and key development programs at the Jefferies 2011 Global Life Sciences Conference at the Grand Hyatt Hotel in New York City, U.S.

LEUVEN, Belgium and LUND, Sweden, May 16, 2011 - ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International AB (OMXS: BINV) announce today that their partner Roche (SIX: RO, ROG; OTCQX: RHHBY) has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).
Older News
S M T W T F S
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
Copyright© 2011 The Gaea Times